Karen Mezzi

600 total citations
41 papers, 356 citations indexed

About

Karen Mezzi is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Health, Toxicology and Mutagenesis. According to data from OpenAlex, Karen Mezzi has authored 41 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 22 papers in Physiology and 4 papers in Health, Toxicology and Mutagenesis. Recurrent topics in Karen Mezzi's work include Chronic Obstructive Pulmonary Disease (COPD) Research (25 papers), Asthma and respiratory diseases (22 papers) and Respiratory and Cough-Related Research (12 papers). Karen Mezzi is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (25 papers), Asthma and respiratory diseases (22 papers) and Respiratory and Cough-Related Research (12 papers). Karen Mezzi collaborates with scholars based in Switzerland, United States and United Kingdom. Karen Mezzi's co-authors include Robert Fogel, Κonstantinos Κostikas, Donald Banerji, Steven S. Shen, Björn Ställberg, Ioanna Tsiligianni, Jadwiga A. Wedzicha, Leif Jørgensen, Gunnar Johansson and F Gutzwiller and has published in prestigious journals such as CHEST Journal, European Respiratory Journal and Thorax.

In The Last Decade

Karen Mezzi

39 papers receiving 349 citations

Peers

Karen Mezzi
Pei Z. Li Canada
María Victorina López-Varela Uruguay
D. Soussan France
Hafida Nekach United States
Damijan Eržen Canada
Annette Kainu Finland
Henna Kupiainen Finland
Pascale Nesme‐Meyer France
Cole Bowerman Canada
Ralf J.P. van der Valk United Kingdom
Pei Z. Li Canada
Karen Mezzi
Citations per year, relative to Karen Mezzi Karen Mezzi (= 1×) peers Pei Z. Li

Countries citing papers authored by Karen Mezzi

Since Specialization
Citations

This map shows the geographic impact of Karen Mezzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Mezzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Mezzi more than expected).

Fields of papers citing papers by Karen Mezzi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Mezzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Mezzi. The network helps show where Karen Mezzi may publish in the future.

Co-authorship network of co-authors of Karen Mezzi

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Mezzi. A scholar is included among the top collaborators of Karen Mezzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Mezzi. Karen Mezzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Κostikas, Κonstantinos, Jorge Máspero, Kenneth R. Chapman, et al.. (2023). Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study. Respiratory Medicine. 217. 107334–107334. 3 indexed citations
3.
Zyl-Smit, Richard N. van, Huib A.M. Kerstjens, Jorge Máspero, et al.. (2023). Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses. Pulmonary Therapy. 9(3). 395–409. 2 indexed citations
4.
5.
Zyl-Smit, Richard N. van, Huib A.M. Kerstjens, Jorge Máspero, et al.. (2023). Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study. Respiratory Medicine. 211. 107172–107172. 5 indexed citations
6.
Larsson, Kjell, Karin Lisspers, Björn Ställberg, et al.. (2022). Treatment Patterns, Socioeconomic Status and Clinical Burden in Mild COPD: A Swedish Real-World, Retrospective Cohort Study, the ARCTIC Study. International Journal of COPD. Volume 17. 1409–1421. 4 indexed citations
7.
Larsson, Kjell, Christer Janson, Karin Lisspers, et al.. (2021). The Impact of Exacerbation Frequency on Clinical and Economic Outcomes in Swedish COPD Patients: The ARCTIC Study. International Journal of COPD. Volume 16. 701–713. 16 indexed citations
8.
Rahérison, Chantal, Karen Mezzi, Κonstantinos Κostikas, Alexander Mackay, & Dave Singh. (2021). The Perception of Physicians on Gender-Specific Differences in the Diagnosis of COPD: Results from a Questionnaire-Based Survey. International Journal of COPD. Volume 16. 901–907. 4 indexed citations
9.
Janson, Christer, Karin Lisspers, Björn Ställberg, et al.. (2020). Osteoporosis and fracture risk associated with inhaled corticosteroid use among Swedish COPD patients: the ARCTIC study. European Respiratory Journal. 57(2). 2000515–2000515. 23 indexed citations
10.
Halpin, David, Claus Vogelmeier, Karen Mezzi, et al.. (2020). Efficacy of indacaterol/glycopyrroniumversussalmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials. ERJ Open Research. 7(1). 816–2020. 4 indexed citations
11.
Barrecheguren, Míriam, Κonstantinos Κostikas, Karen Mezzi, et al.. (2020). COPD clinical control as a predictor of future exacerbations: concept validation in the SPARK study population. Thorax. 75(4). 351–353. 12 indexed citations
12.
Ställberg, Björn, Christer Janson, Karin Lisspers, et al.. (2020). Inhaled corticosteroids and the risk of type 2 diabetes among Swedish COPD patients. npj Primary Care Respiratory Medicine. 30(1). 47–47. 7 indexed citations
13.
Lisspers, Karin, Kjell Larsson, Christer Janson, et al.. (2019). Gender differences among Swedish COPD patients: results from the ARCTIC, a real-world retrospective cohort study. npj Primary Care Respiratory Medicine. 29(1). 45–45. 41 indexed citations
14.
Wedzicha, Jadwiga A., Dave Singh, Ioanna Tsiligianni, et al.. (2019). Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study. Respiratory Research. 20(1). 4–4. 18 indexed citations
15.
Anzueto, Antonio, Κonstantinos Κostikas, Karen Mezzi, et al.. (2018). Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study. Respiratory Research. 19(1). 121–121. 30 indexed citations
16.
Vogelmeier, Claus, Nanshan Zhong, Michael Humphries, et al.. (2016). Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis. International Journal of COPD. Volume 11. 3189–3197. 12 indexed citations
17.
Wedzicha, Jadwiga A., Anthony D’Urzo, Karen Mezzi, et al.. (2014). QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK study. European Respiratory Journal. 44(Suppl 58). 1893–1893. 2 indexed citations
18.
Mezzi, Karen, et al.. (2014). LABA/LAMA Dual Bronchodilation as a Paradigm Shift in COPD Therapy: Overview of the QVA149 IGNITE Program. CHEST Journal. 145(3). 402A–402A. 1 indexed citations
19.
Dubus, J.‐C., J. Montharu, Laurent Vecellio, et al.. (2007). Lung Deposition of HFA Beclomethasone Dipropionate in an Animal Model of Bronchopulmonary Dysplasia. Pediatric Research. 61(1). 21–25. 5 indexed citations
20.
Dubus, J.‐C., J. de Blic, & Karen Mezzi. (2004). Rôle des petites voies aériennes dans l’asthme de l’enfant. Revue des Maladies Respiratoires. 21(4). 737–742. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pei Z. Li Breakdown of academic impact, for papers by María Victorina López-Varela Breakdown of academic impact, for papers by D. Soussan Breakdown of academic impact, for papers by Hafida Nekach Breakdown of academic impact, for papers by Damijan Eržen Breakdown of academic impact, for papers by Annette Kainu Breakdown of academic impact, for papers by Henna Kupiainen Breakdown of academic impact, for papers by Pascale Nesme‐Meyer Breakdown of academic impact, for papers by Cole Bowerman Breakdown of academic impact, for papers by Ralf J.P. van der Valk
Rankless by CCL
2026